Adage Capital Partners Gp, L.L.C. Viridian Therapeutics, Inc.\De Transaction History
Adage Capital Partners Gp, L.L.C.
- $54.9 Billion
- Q4 2024
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 1,670,000 shares of VRDN stock, worth $25.5 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
1,670,000
Previous 1,205,000
38.59%
Holding current value
$25.5 Million
Previous $27.4 Million
16.78%
% of portfolio
0.06%
Previous 0.05%
Shares
2 transactions
Others Institutions Holding VRDN
# of Institutions
200Shares Held
79.4MCall Options Held
477KPut Options Held
917K-
Black Rock Inc. New York, NY4.77MShares$72.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.6MShares$70.1 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.52MShares$69 Million3.82% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$59.3 Million12.28% of portfolio
-
State Street Corp Boston, MA3.52MShares$53.8 Million0.0% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $609M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...